LINDE PLC (LIN): what the price requires
At today's price, LINDE PLC (LIN) is priced for +21.4% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.
Generated: 2026-07-13 · Source: https://boothcheck.com/report/LIN
Headline
| Field | Value |
|---|---|
| Ticker | LIN |
| Company | LINDE PLC |
| Current price | $523.42/sh |
| Composition | Merchant 30% / On-Site 24% / Packaged Gas 35% / Other 11% |
What The Price Requires (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | whole-company |
| Operating margin needed | 15.9% |
| Operating margin today | 27.5% |
| Margin compression implied | -11.6pp |
| Implied growth | 21.4% |
| Multiple paid | 28x operating income |
The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.
Solve inputs: computed at a 8.5% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~8.2pp.
How unusual the bet is: within-range
| Reference | Value |
|---|---|
| vs own history | -0.02σ |
| cohort percentile (of 76 peers) | 79 |
| sustained it ~5 years at this level | 40% |
| implied end-window share | 0% |
Valuation X-Ray
Every valuation family lands below the price. The price therefore requires assumptions beyond what those standard frames encode.
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | 3.12x | 5 | expensive |
| Earnings | 3.99x | 4 | expensive |
| Relative | 2.89x | 5 | expensive |
| Growth | 1.31x | 3 | expensive |
Families that call it expensive: Asset, Earnings, Relative
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.4%); the inversion above states its own rate.
Per-Model Detail (n=17)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | $206.29 | 2.54x | yes | FCF base $5.1B, growth 5% (input: historical growth), terminal g 4.0%, WACC 8.4%, 6yr projection |
| DCF Exit Multiple | Growth | $442.22 | 1.18x | yes | Exit EV/EBITDA: 18.5x / 20.5x / 22.5x (bear / base = today's held flat / bull), 6yr |
| Relative Valuation | Relative | $300.24 | 1.74x | yes | P/E 20.14x (blended: sector 14x + trailing (TTM) 34x), scenarios: 16.8x / 20.1x / 23.4x (bear / base = sector held flat / bull), EV/EBITDA 11.76x |
| Simple DDM | Growth | — | — | no | — |
| Two-Stage DDM | Growth | — | — | no | — |
| Simple Excess Return | Asset | $164.18 | 3.19x | yes | BV/sh $82.70, ROE (TTM) 18.4%, ke 9.3% |
| Two-Stage Excess Return | Asset | $228.46 | 2.29x | yes | 5yr excess ROE then converge to ke=9.3% |
| Discounted Future Market Cap | Growth | $399.09 | 1.31x | yes | Rev $34.7B, growth 5% (input: historical growth; tapered), Terminal P/S: 5.9x / 7.0x / 8.2x (bear / base = today's held flat / bull, cap 8x) |
| Peter Lynch Fair Value | Relative | $180.96 | 2.89x | yes | EPS $15.08, growth 10% (input: historical EPS growth), PEG=3.47 (Overvalued) |
| Margin Trajectory | Growth | — | — | no | — |
| Earnings Power Value | Earnings | $109.68 | 4.77x | yes | Normalized EBIT (5y avg op income, one-time charges added back) $7.79B × (1−21%) / WACC 8.4% → EPV (no growth) |
| Residual Income | Asset | $226.01 | 2.32x | yes | BV $82.70 + 5yr PV of (ROE (TTM) 18.4% − Kₑ 9.3%) × BV; BV grows 8.8%/yr |
| Graham Number | Asset | $167.51 | 3.12x | yes | √(22.5 × EPS $15.08 × BVPS $82.70) — Graham's conservative floor |
| EV/EBITDA Relative | Relative | $174.77 | 2.99x | yes | EBITDA $12.98B × sector EV/EBITDA 8.0x |
| FCF Yield | Earnings | $70.20 | 7.46x | yes | FCF $5096.0M / Kₑ 9.3% — zero-growth perpetuity |
| SBC-Adj FCF Yield | Earnings | — | — | no | — |
| Ben Graham Formula | Earnings | $358.29 | 1.46x | yes | EPS $15.08 × (8.5 + 2×9.9%) × (4.4 / 5.3%) |
| ROIC-Justified P/B | Asset | $31.26 | 16.74x | yes | BV $82.70 × (ROIC 3.2% / WACC 8.4%) |
| P/Sales Sector | Relative | $111.47 | 4.70x | yes | Revenue $34.66B × sector P/S 1.5x |
| PEG Fair Value | Relative | $224.49 | 2.33x | yes | EPS $15.08 × (PEG 1.5 × growth 9.9% (input: historical EPS growth)) → PE 14.9x |
| Earnings Yield | Earnings | $163.03 | 3.21x | yes | EPS $15.08 / required return 9.3% (Rf 4.3% + ERP 5.0%) |
| Funds From Operations Multiple | Relative | — | — | no | — |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Solvency
| Field | Value |
|---|---|
| Net debt | $22.6b |
| Net debt / NOPAT (after-tax) | 3.06x |
| Net debt / operating income (pre-tax) | 2.42x |
| Interest coverage | 36.9x |
| Share count CAGR (buyback) | -2.3% |
| Burning cash | no |
Bullet Takeaways
- Linde is the world's largest industrial-gas company, and its economics rest on long-term on-site supply contracts that the 10-K describes as "long-term supply arrangements which generally require the customer to purchase their requirements from Linde" with minimum purchase and price-escalation terms, the structural source of its pricing power.
- The defining risk is the price itself: the stock trades at roughly 28 times company-wide operating income, at the very top of its peer distribution and beyond what any standard valuation family reaches.
- The next markers are quarterly margin and volume: Q1 FY2026 lifted operating margin to about 30% on pricing and productivity even as industrial volumes stayed soft in Europe and Asia, and management raised full-year EPS guidance, so watch whether price keeps doing the work that volume is not.
Bull Case
One number decides the Linde thesis, and it is the operating margin: about 26.5% on a trailing basis and roughly 30% in the most recent quarter, a level almost no company that sells a physical commodity ever reaches. Industrial gases are, on paper, a commodity, oxygen and nitrogen separated from air. Linde earns chemical-company volumes at software-adjacent margins, and if that margin holds, the entire premium valuation has a foundation. If it slips, the premium has nothing under it. Everything else in the bull case is an explanation of why that one number is durable.
The durability comes from contract structure, not from any secret in the chemistry. The 10-K describes Linde's relationships with its largest customers as "long-term supply arrangements which generally require the customer to purchase their requirements from Linde", arrangements with "minimum purchase requirements" and price-escalation provisions. A steel mill or semiconductor fab that takes its gas from an on-site Linde plant cannot easily switch: the plant is built next to the customer, the contract runs for years, and the price rises with cost by formula. That is take-or-pay revenue dressed as a commodity sale, and it is why Linde's most recent quarter could grow earnings on price and productivity even while volumes were flat. The filing adds a quiet edge: those on-site plants "also produce liquid products for the merchant market", so a single asset serves a contracted customer and an open market at once, and is "typically not dedicated to a single customer."
Capital discipline finishes the case. Return on equity runs around 18.4% against book value of $82.70 a share, the company converts roughly $5 billion a year into free cash flow, and share count has been shrinking about 2.3% annually, so the per-share base compounds without the company needing volume growth it cannot get from a mature industrial economy. Interest coverage near 16 times means the $22.6 billion of net debt is comfortably serviced. The bull case is not that Linde grows fast; it is that it earns an exceptional, contract-protected margin on a slow-growing base and returns the difference, which is precisely the profile that justifies a premium to the broad chemicals group it is sorted against.
Bear Case
Start with the qualitative truth before the ratio: there is no version of the standard analysis that calls Linde cheap, or even fairly priced. The bear case is not that the company is bad; it is that the price has detached from every method used to value it. The asset-value lens, the earnings-power lens, the peer-multiple lens, and even the forward-growth lens all read the stock as expensive, several of them by a factor of three or more. When no valuation family reaches the price, the stock is no longer being priced on its economics; it is being priced as a quality compounder the market refuses to let trade at a normal multiple, and that is a fragile equilibrium because it depends on sentiment about safety rather than on any cash flow the methods can find.
Translate the disconnect into the arithmetic. At roughly 28 times company-wide operating income, the price requires operating profit to grow about 21% a year for five years. Set that against a company that grew revenue about 5% in its base period and lifted earnings in its most recent quarter primarily through price and productivity rather than volume. The multiple sits at the very top of the peer distribution, well beyond the upper quartile, and only about 41% of comparable fast-growers historically sustained that pace for even five years. The earnings-power method, which capitalizes normalized operating profit with no growth credit, lands near a fifth of the price; the book-value-plus-profitability methods land near a third. If the premium multiple ever compresses toward where the static methods sit, the price has a long way to fall regardless of how well the business itself performs, because the business is not the problem; the multiple is.
The operating risk that could trigger that compression is demand. Linde's most recent results leaned on pricing precisely because industrial volumes were soft in Europe and parts of Asia-Pacific, and a company priced for 21% profit growth has no margin for a prolonged volume drought in its core regions. Pricing power is real but not infinite; cost-plus escalation defends margin, it does not manufacture the volume growth the multiple assumes. The balance sheet carries $22.6 billion of net debt, well-covered today, but it is the kind of leverage that turns from comfortable to constraining if a demand downturn coincides with the company needing to fund the large fixed capital its on-site model requires. The bear does not need Linde to stumble operationally. It only needs the market to decide that a top-of-cohort multiple on a mid-single-digit grower was too much.
Valuation
Linde is priced as if it were a high-growth company, and it is not one. At today's level the market pays roughly 28 times company-wide operating income, and inverting that price implies operating profit growth of about 21% a year for five years. The company's recent record is mid-single-digit revenue growth, with the most recent quarter's earnings gain coming from price and productivity rather than volume. The gap between what the price assumes and what the business delivers is the whole valuation: the price is not buying Linde's growth, it is buying Linde's certainty, and paying a high-growth multiple for it.
The method disagreement is unusually one-sided. No valuation family reaches the price. The forward-growth lens comes closest, with an exit-multiple DCF landing within range only by holding today's EV/EBITDA near 20 times flat for the forecast, but the perpetual-growth DCF, crediting Linde's actual roughly 5% growth, lands at less than half the price. The peer-multiple lens reads the stock as expensive against a blended sector P/E near 20 times. The earnings-power method, capitalizing normalized operating profit with no growth, sits near $110 against a market price above $500. And the asset-value methods land in the low-to-mid $200s, because even an 18.4% return on equity, capitalized properly, does not generate enough excess return over a $82.70 book value to support the price. The pattern is not ambiguous: every frame anchored on demonstrated economics says the price is a premium beyond what the methods support, and only a multiple held flat in perpetuity defends it.
The cohort comparison has to be read carefully, because the reported peer set, the commodity chemicals and fertilizer names like Dow, Eastman, CF Industries, and Mosaic, is not Linde's true economic peer group. Those businesses are cyclical price-takers; Linde is a contract-protected margin compounder, which is exactly why it trades at the top of that distribution and why a simple comparison to the group median understates how unusual its profitability is. The honest read is that Linde deserves a premium to commodity chemicals, but the size of the premium is the question, not the existence of it. Solvency is not the worry: net debt of $22.6 billion is covered roughly 16 times by operating profit, and the company funds its capital program from internal cash. The decisive fact is the multiple. The buyer at today's price is underwriting that the market keeps awarding Linde a top-of-cohort multiple on a business growing at the bottom of the growth range, indefinitely.
Catalysts
The Q1 FY2026 print was a clean beat-and-raise on the quality the bull cares about. Revenue rose 8.2% year over year to $8.78 billion, operating profit grew 8% to $2.6 billion at roughly a 30% margin, and management raised full-year EPS guidance to a $17.60 to $17.90 range with a Q2 outlook of $4.40 to $4.50. The composition of the beat is the story: management attributed it to pricing and cost productivity rather than broad volume growth, with margins improving about 50 basis points sequentially even as seasonal volumes declined.
That same composition names the catalyst risk. The earnings strength came despite weak industrial demand in Europe and parts of Asia-Pacific, and the company's own framing is that subdued conditions in those regions could pressure volumes if they persist. For a stock priced for 21% profit growth, the volume recovery in those core industrial regions is the swing variable, and it is the one Linde controls least. The pricing lever has carried earnings through the soft patch, but pricing escalation is a margin defense, not a growth engine, and the market is paying for growth.
The watch items are concrete and quarterly. Track whether operating margin holds near 30% as the pricing comparisons get harder, whether industrial volumes in Europe and Asia turn, and the pace of capital deployment into new on-site projects, since the long-term supply backlog is what converts today's capital into tomorrow's contracted, margin-protected revenue. Management's disciplined capital returns, the steady buyback and dividend, support the per-share math, but the print that would actually justify the multiple is one where volume rejoins price as a growth driver rather than substituting for it.
Peer Cohorts (Per Segment, With Filing Citations)
Engineering (reported)
- APD (AIR PRODUCTS AND CHEMICALS, INC.)
- (no filing in the citation store)
- DOW (Dow Inc.)
- (no filing in the citation store)
- LYB (LYONDELLBASELL INDUSTRIES N.V.)
- (no filing in the citation store)
- WLK (Westlake Corporation)
- (no filing in the citation store)
- CE (CELANESE CORPORATION)
- (no filing in the citation store)
- EMN (EASTMAN CHEMICAL CO)
- (no filing in the citation store)
- DD (DUPONT DE NEMOURS, INC.)
- (no filing in the citation store)
- CC (Chemours Co)
- (no filing in the citation store)
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.
Sources
Q1 FY2026 earnings release · FY2024 10-K · Q1 FY2026 earnings call